癌理通膏治疗骨肿瘤患者的临床疗效及安全性研究

Clinical Efficacy and Safety of Ailitong Ointment on Patients with Bone Tumor

目的:探讨癌理通膏外敷法辅助治疗骨肿瘤患者癌性疼痛的临床疗效及安全性。方法:选取2014年2月—2016年3月医院收治的骨肿瘤患者98例为研究对象,随机分为观察组与对照组,观察组患者给予癌理通膏外敷辅助治疗,对照组患者给予奥施康定辅助治疗。对比两组患者治疗后疼痛缓解情况、治疗前后生活质量以及治疗前后血清神经生长因子(NGF)、内皮素(ET-1)、β-内啡肽、肿瘤坏死因子-α(TNF-α)水平,并观察两组患者不良反应发生情况。结果:与对照组对比,观察组患者疼痛缓解总有效率显著升高(P<0.05);与治疗前对比,治疗后观察组患者的KPS评分明显升高,且明显高于对照组治疗后的KPS评分(P<0.05);与治疗前对比,治疗后观察组与对照组患者的NGF、TNF-α及ET-1均明显降低,β-EP明显升高,且治疗后观察组患者各指标较对照组变化更明显(P<0.05);观察组不良反应发生率为20.41%,对照组患者不良反应发生率为18.37%,两组对比无显著差异(P>0.05)。结论:癌理通膏外敷辅助治疗骨肿瘤患者能够显著缓解患者癌性疼痛,改善患者生活质量,值得临床推广应用。

Objective ： To investigate the clinical efficacy and safety of Ailitong Ointment in adjuvant treatment of bone tumors patients with cancer pain. Methods： From February 2014 to March 2016 in our hospital,98 cases of bone tumor patients as the research object, were randomly divided into observation group and control group. The observation group was treated with Ailitong Ointment adjuvant therapy. The eontrol group wss treated with oxycontin. Pain relief was com- pared between two groups after treatment. The quality of life before and after treatment and after treatment serum nerve growth factor （NGF）, endothelin （ET - 1 ）, beta endorphin, tumor necrosis factor alpha （TNF -α） levels and the oc- currence of adverse reactions in the two groups were observed. Results ： Compared with the control group, the observation group＇ s total effective rate of pain relief was significantly increased （P 〈 0. 05 ）. Compared with those before treatment, the KPS score of the observation group after treatment was significantly increased and significantly higher than the control group＇ s after treatment （P 〈 0. 05）. Compared with those before treatment, the observation group and the control group＇ s NGF alpha, TNF - α and ET - 1 after treatment were decreased, beta - EP increased significantly, and the observation group＇ s indexes after treatment group had significant changes compared with those of the control group（P 〈 0.05 ）. The incidence of adverse reactions was 20.41% and the control group＇ s was 18.37%. There was no significant difference be- tween the two groups （ P 〉 0. 05 ）. Conclusion： Ailitong Oniment adjuvant treatment of bone tumor can significantly allevi- ate the pain of cancer and improve the quality of life of patients, worthy of clinical application.